Accepted Article This article is protected by copyright. All rights reserved. Baseline characteristics of patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR) - TIMI 53 Trial Short Running Title: SAVOR –TIMI 53 trial patient baseline characteristics Mosenzon O MD 1 , Raz I MD 1 , Scirica BM MD, MPH 2 , Hirshberg B MD 3 , Stahre CI MD 4 , Steg PG MD 5 , Davidson J MD 6 , Ohman P MD 3 , Price DL 3 , Frederich B MD, PhD 7 , Udell JA MD 2 , Braunwald E MD 2 Bhatt DL MD, MPH 2,8 1 Diabetes Unit, Department of Medicine, Hadassah University Hospital, Jerusalem, Israel 2 TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 3 AstraZeneca Research and Development, Wilmington, DE 4 AstraZeneca Research and Development, Mölndal, Sweden 5 Université Paris-Diderot, Sorbonne Paris-Cité, INSERM U-698, CHU Bichat, AP- HP, Paris, France 6 Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas, TX 7 Bristol-Myers Squibb, Princeton, NJ 8 VA Boston Healthcare System, Boston, MA This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/dmrr.2413